EMD 503982
Latest Information Update: 31 Oct 2007
At a glance
- Originator Merck KGaA
- Class Antithrombotics
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arterial thrombosis; Venous thrombosis
Most Recent Events
- 31 Oct 2007 Discontinued - Phase-I for Arterial thrombosis in USA (PO)
- 31 Oct 2007 Discontinued - Phase-I for Venous thrombosis in USA (PO)
- 08 Jun 2006 Phase-I clinical trials in Arterial thrombosis in USA (unspecified route)